Brodalumab: 5-Year US Pharmacovigilance Report

By sjmartinez • May 10, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb). 2024 May 9. doi: 10.1007/s13555-024-01162-8. Epub ahead of print. PMID: 38724839.

Tags: Adverse events, Dermatology, Drug reaction, psoriasis, Publications, real-world, safety

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]

Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of Secondary Pathologic Consultation

Zhang R, Yueh K, Anderson M, Bennett RG. Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of[...]